Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Short Communication

Rapid screening for SARS-CoV-2 VOC-Alpha (202012/01, B.1.1.7) using the Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay

Nicla Giovacchini 1, Marco Coppi 1,2, Noemi Aiezza 1, Ilaria Baccani 1, Francesca Malentacchi 2, Simona Pollini 1,2, Alberto Antonelli 1,2, Gian Maria Rossolini 1,2,*

1 Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
2 Microbiology and Virology Unit, Careggi University Hospital, Florence, Italy

A R T I C L E   I N F O

Article history:
Received 18 June 2021
Revised 1 September 2021
Accepted 2 October 2021

Keywords:
Rapid screening method
SARS-CoV-2 VOC
B.1.1.7 lineage

A B S T R A C T

Background: The emergence of SARS-CoV-2 variants of concern (VOCs) for increased transmissibility and being potentially capable of immune-escape mandates for epidemiological surveillance. Genetic alterations present in VOCs can affect the results of RT-qPCR assays for routine diagnostic purposes, leading to peculiar profiles that can be used for rapid screening of variants. This study reports a peculiar profile observed with the Allplex™ SARS-CoV-2/FluA/FluB/RSV assay and VOC-Alpha (202012/01, lineage B.1.1.7, also named VOC-UK), which was the first identified SARS-CoV-2 VOC.

Methods: Samples were analyzed by two RT-qPCR assays: the Allplex™ SARS-CoV-2/FluA/FluB/RSV assay (ASFR, Seegene Technologies Inc; Seoul, South Korea) and the TaqPath COVID-19 RT-PCR (Thermo Fisher Scientific, USA). Definition of the SARS-CoV-2 variant was carried out by Sanger sequencing of the relevant S-gene regions and, in some cases, by whole genome sequencing (WGS) using the ARTIC-nCoV workflow on a MiniION (Oxford Nanopore Technologies, Oxford, UK) or a Illumina MiSeq platform (San Diego, California, USA).

Results: Of the 173 SARS-CoV-2-positive specimens, all of those of lineage B.1.1.7 (N=71) showed an average Cq difference between the N and S genes of +11±2 (range, +8/+15). None of the other specimens, including several different lineages (Wild-type for the analyzed regions, N=22; Gamma, N=63; Delta, N=9; B.1.258Δ, N=3; B.1.160, N=3; B.1.177.7, N=1; B.1.1.420, N=1), exhibited a similar difference in Cq values.

Conclusions: The peculiar pattern of delayed N gene positivity could constitute a convenient method for VOC-Alpha screening, simultaneous to viral detection, when using the Allplex™ SARS-CoV-2/FluA/FluB/RSV assay.

© 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

The current SARS-CoV-2 pandemic has crucially affected populations and healthcare systems worldwide. One of the challenges posed by SARS-CoV-2, similar to other RNA viruses, is represented by genomic variability, which may lead to the emergence of variants with improved transmissibility, increased virulence and/or immune-escape ability. Variants for which clear evidence is available about such modified features, which are likely to have an epidemiological impact, have been categorized as variants of concern (VOCs) (ECDC, 2020). Among them, VOC-Alpha (202012/01, belonging to the B.1.1.7 lineage, also named VOC-UK) was the first to be identified. Indeed, this variant rapidly disseminated worldwide, becoming the dominant circulating lineage in several areas, due to its higher transmissibility (Leung et al., 2021). VOC-Alpha is defined by multiple spike protein alterations, including His69-Val70 and Tyr144 deletions, and amino acid substitutions Asn501Tyr, Ala570Asp, as well as alterations in other proteins (e.g. Asp3Leu and Ser235Phe in the N nucleocapsid protein) (Haynes et al., 2021).

The emergence and spread of SARS-CoV-2 variants has mandated for their epidemiological surveillance. Although sequencing the entire viral genome represents the reference approach for variant identification, it is expensive and time-consuming and requires specialized laboratories. Therefore, there is considerable interest for rapid molecular methods able to screen for VOCs, which could be helpful to rapidly detect their presence by routine lab-

https://doi.org/10.1016/j.ijid.2021.10.005
1201-9712/© 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Table 1
Summary of the results obtained from 173 specimens positive for SARS-CoV-2, analyzed with the AFSR and TaqPath COVID-19 RT-PCR assays.

| Lineage         | ASFR N. of specimens | Average ΔCq (N-S genes) | TaqPath Cq range | Missing S-gene target amplification |
|-----------------|-----------------------|--------------------------|------------------|-------------------------------------|
| Alpha (B.1.1.7) | 71                    | +11                      | from +8 to +115  | 71                                  |
| Gamma (P1)      | 63                    | +1                       | from -2 to +5    | 0                                   |
| Delta (B.1.617.2) | 9                    | +4                       | from -1 to +6    | 0                                   |
| B.1.258Δ        | 3                     | -2                       | from -4 to 0     | 3                                   |
| B.1.160         | 3                     | 0                        | from -1 to 0     | 0                                   |
| B.1.177.7       | 1                     | -1                       | 0                | 0                                   |
| B.1.1.420       | 1                     | -1                       | -1               | 0                                   |
| Wild-type*      | 22                    | -1                       | from -3 to +1    | 0                                   |

*Wild-type for the analyzed regions by Sanger sequencing

This study reports the observation that VOC-UK could be easily and rapidly detected by analyzing the results of the profiles obtained by the Allplex™ SARS-CoV-2/FluA/FluB/RSV assay (AFSR, Seegene Technologies Inc; Seoul, South Korea). AFSR is a multiplex real-time RT-PCR assay targeting the N, RdRP and S genes of SARS-CoV-2, along with influenza A, influenza B and respiratory syncytial virus (RSV). A collection of 173 SARS-CoV-2-positive, non-repeatable, nosopharylgeal swabs were evaluated. All samples, residual from the diagnostic routine, were anonymized for the purpose of this study. The SARS-CoV-2 lineage was presumptively assigned by characterization of two regions of the S gene (21663-22036 bp and 22772-23460 bp) by Sanger sequencing. Twenty-three specimens were also subjected to whole genome sequencing (WGS) by the ARTIC-nCoV workflow using a MinIOn platform (Oxford Nanopore Technologies, Oxford, UK) or by the EasySeq RCP SARS-CoV-2 Whole Genome Sequencing kit (NimaGen BV, Niijmegen, NL) on an Illumina MiSeq platform (San Diego, USA). Overall, the collection included 75 specimens (which five were confirmed by WGS) of the B.1.1.7 lineage, 63 specimens (of which one was confirmed by WGS) of the P.1 lineage, nine specimens of the Delta (B.1.617.2) lineage (all confirmed by WGS), and 30 specimens belonging to other lineages not currently included among VOCs (of which eight were confirmed by WGS). (Table 1).

In addition to the AFSR assay, all specimens were also analyzed with the TaqPath COVID-19 RT-PCR, which has been used for rapid screening of VOC-UK (Kidd et al., 2021). Analysis of the results obtained with specimens of the B.1.1.7 lineage always revealed a notable difference between the Cq values for the N and S genes (mean, +11±2; range, +8 to +15), while such a difference was not observed with specimens of the other lineages (Table 1). The TaqPath COVID-19 RT-PCR assay revealed a missing S-gene target amplification with all specimens of VOC-UK, but also with B.1.258Δ (Table 1), as expected from the presence of the HV69-70 spike deletion also in members of this lineage (Brejova et al., 2021).

The delayed detection of the N-gene target (i.e. higher Cq values) with the ASFR assay might be due to the presence of mutations 28280 GAT->CTA and 289777 in the N nucleocapsid gene, likely affecting the oligonucleotide/probe region and leading to lower RT-qPCR efficiency.

In conclusion, these data suggest that finding a considerably higher (>8) N-gene Cq value vs. S-gene Cq value could be highly suggestive of the presence of VOC-UK at the same time as viral detection. The delayed N-gene target amplification by the ASFR assay may constitute a more specific proxy for VOC-UK compared with the TaqPath test, which presumptively identifies VOC-UK based on a missing S-gene target amplification due to the presence of HV69-70 deletion, which is also present in other lineages such as B.1.258Δ. In fact, members of the latter lineage did not present a delayed N-gene amplification with the ASFR assay (Table 1).

Further experiments, including additional variants with alterations in the N-gene sequence, will be required to confirm the specificity of the ASFR “N-late” method for rapid screening of VOC-UK. Similar approaches, based on modified patterns of results obtained with commercial diagnostic resources routinely used for SARS-CoV-2 detection, could be of interest for inexpensive and large-scale epidemiological surveillance of viral variants.

DECLARATION OF COMPETING INTEREST

Dr. Antonelli reports personal fees from Accelerate diagnostics, personal fees from Arrow diagnostics, personal fees from Menarini, personal fees from Seegene, non-financial support from Symcel, outside the submitted work.

Dr. Rossolini reports grants, personal fees and non-financial support from Accelerate Diagnostics, personal fees from Becton Dickinson, grants and personal fees from bioMérieux, grants and personal fees from Cepheid, grants and personal fees from Elitech, grants and personal fees from Merck, grants and personal fees from Nordic Pharma, personal fees from Pfizer, grants from Seegene, grants and personal fees from Shionogi, personal fees and other from Venatorx, grants and personal fees from Zambon, personal fees from Roche, personal fees from Thermo Fisher, personal fees and non-financial support from Beckman Coulter, grants, personal fees and non-financial support from Menarini, grants from Arrow, grants from Symcel, personal fees from QPex, grants from DID, grants from Hain Lifescience GmbH, grants from GenePoc, grants from Setlance, grants and personal fees from Angellini, grants from Quella, grants from Qlinea, personal fees from Qiagen, grants from Biomedical Service, grants from Lioflichem, outside the submitted work.

Dr. Baccani reports for Diese-Diagnostica Senese, outside the submitted work.

All other authors have nothing to disclose.

ACKNOWLEDGEMENTS

This study was supported by internal funding.
AUTHOR STATEMENT

NG wrote the original draft, which was reviewed and edited by GMR, MC, AA, FM and SP. The study was conceived by NG, GMR, AA and MC; investigation was performed by NG, NA and IB; resources were accessed by GMR; NG, NA, IB, MC and AA contributed to the methodology; NG, MC and AA contributed to the formal analysis; project administration was by GMR and SP.

ETHICAL APPROVAL STATEMENT

Results were obtained from the analysis of anonymized data derived from diagnostic routine testing.

REFERENCES

Brejová B, Boršová K, Hodorová V, et al. A SARS-CoV-2 mutant from B.1.258 lineage with ΔH69/ΔV70 deletion in the Spike protein circulating in Central Europe in the fall 2020. Virus Genes 2021; Aug 27:1–5. doi: 10.1007/s11262-021-01866-5.

European Centre for Disease Prevention and Control. Assessing SARS-CoV-2 circulation, variants of concern, non-pharmaceutical interventions and vaccine rollout in the EU/EEA, 15th update – 10 June 2021. https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-sars-cov-2-circulation-variants-concern.

Haynes W, Kamath K, Lucas C, et al. Impact of B.1.1.7 variant mutations on antibody recognition of linear SARS-CoV-2 epitopes. medRxiv 2021; 01.06.20248960.

Kidd M, Richter A, Best A, et al. S-variant SARS-CoV-2 lineage B1.1.7 is associated with significantly higher viral loads in samples tested by Thermo Fisher TaqPath RT-qPCR. J Infect Dis 2021; 223(10):1666–70. doi: 10.1093/infdis/jiab082.

Leung K, Shum MH, Leung GM, et al. Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020. Euro Surveill 2021. doi: 10.2807/1560-7917.ES.2020.26.1.2002106.

Tyson JR, James P, Stoddart D, et al. Improvements to the ARTIC multiplex PCR method for SARS-CoV-2 genome sequencing using nanopore. bioRxiv 2020. doi: 10.1101/2020.09.04.283077.